Related Experiment Videos
p16(MTS-1/CDKN2/INK4a) in cancer progression
1Department of Otology and Laryngology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts 02114, USA.
Experimental Cell Research
|March 10, 2001
Summary
The tumor suppressor p16, an inhibitor of cyclin-dependent kinases 4 and 6, is crucial in cancer. Its frequent loss early in tumor progression highlights its role in carcinogenesis and familial melanoma.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The tumor suppressor p16 is a key inhibitor of cyclin-dependent kinases 4 and 6.
- Its significance in cancer has grown since its discovery.
- High frequencies of p16 deletions in tumor cell lines suggested its role in carcinogenesis.
Purpose of the Study:
- To explore the role of the tumor suppressor p16 in cancer development.
- To investigate the mechanisms of p16 inactivation in various cancers.
Main Methods:
- Analysis of p16 gene deletions in tumor cell lines.
- Genetic studies in kindreds with familial melanoma.
- Examination of p16 gene alterations in primary tumors.
- Investigation of p16 promoter methylation.
- Genetic analysis of precancerous lesions and tissue culture models.
Main Results:
- p16 deletions are frequent in tumor cell lines.
- p16 inactivation is documented in familial melanoma.
- A high frequency of p16 gene alterations occurs in primary tumors.
- p16 promoter methylation is a major silencing mechanism.
- Loss of p16 is an early and critical event in tumor progression.
Conclusions:
- p16 is a major tumor suppressor gene.
- Frequent loss of p16 occurs early in many human cancers.
- Understanding p16's role is vital for cancer research and therapy.